ライフサイエンスコーパス: parkinsonian syndrome

1 women presenting with a late-onset isolated parkinsonian syndrome.

2 ented with a 4-year history of a progressive parkinsonian syndrome.

3 iatal dopaminergic neurons, which causes the parkinsonian syndrome.

4 protect against toxins that induce an acute parkinsonian syndrome.

5 nd 70 (42 male, 28 female) as having another parkinsonian syndrome.

6 rotid artery, producing a contralateral hemi-parkinsonian syndrome.

7 paminergic lesion associated with an evident parkinsonian syndrome.

8 impact in patients with clinically uncertain Parkinsonian syndromes.

9 orticobasal degeneration from other atypical parkinsonian syndromes.

10 istinguish this disorder from other atypical parkinsonian syndromes.

11 work-up of patients with known or suspected parkinsonian syndromes.

12 maging for diagnosing and managing different parkinsonian syndromes.

13 also being applied to the study of atypical parkinsonian syndromes.

14 rvation occur independently in patients with parkinsonian syndromes.

15 ith respect to the differential diagnosis of Parkinsonian syndromes.

16 maging in patients with clinically uncertain Parkinsonian syndromes.

17 ation may occur early in PD but not in other parkinsonian syndromes.

18 f specific patterns associated with atypical parkinsonian syndromes and classic Parkinson's disease w

19 riatal dopaminergic pathways as seen in most parkinsonian syndromes and in some cases of illicit drug

20 actical use in the differential diagnosis of Parkinsonian syndromes and indeterminate tremors.

21 nge of neurodegenerative diseases, including parkinsonian syndromes and motor neuron disease.

22 mination (ACE-R) could differentiate between parkinsonian syndromes and reflect longitudinal changes

23 metabolic diseases, and genetic dystonic or parkinsonian syndromes) and are, therefore, frequently m

24 in networks in Parkinson's disease, atypical parkinsonian syndromes, and other movement disorders.

25 These findings indicate that (1) in parkinsonian syndromes apart from PSP, the saccade-gener

26 patients with clinically suspected atypical parkinsonian syndrome (APS) were prospectively recruited

27 esirable in patients with suspected atypical parkinsonian syndromes (APSs) for optimal treatment and

28 This is important as atypical parkinsonian syndromes (APSs) such as progressive supran

29 atistical analyses for diagnosis of atypical parkinsonian syndromes are 91.4% and 90.6%, respectively

30 It has been previously reported that a Parkinsonian syndrome can be elicited in the common gold

31 trahydropyridine (MPTP) to cats results in a parkinsonian syndrome characterized by rigidity, akinesi

32 but are rare; most cases with a fairly pure parkinsonian syndrome (eg, young-onset Parkinson's disea

33 On examination, he showed a severe parkinsonian syndrome featuring bradykinesia, rigidity (

34 rogression were compared with other atypical Parkinsonian syndromes from previous QSBB studies.

35 improvements in the characterisation of the parkinsonian syndromes have led to improvements in clini

36 movements in 23 patients with the following parkinsonian syndromes: idiopathic parkinsonism (PD), mu

37 -tetrahydropyridine (MPTP), which produces a Parkinsonian syndrome in experimental animals and humans

38 1) were significantly lower in patients with parkinsonian syndromes in drug-off condition than in hea

39 with spectra obtained from 20 patients with parkinsonian syndromes in drug-on and drug-off condition

40 o compare healthy subjects and patients with parkinsonian syndromes in drug-on or drug-off conditions

41 contributor to the differential diagnosis of parkinsonian syndromes in the correct clinical context.

42 supranuclear palsy (PSP) overlap with other parkinsonian syndromes, including multiple system atroph

43 between Parkinson disease (PD) and atypical parkinsonian syndromes, including multiple-system atroph

44 idiopathic Parkinson's disease from atypical parkinsonian syndromes is challenging, especially in the

45 at 98.6% (72 out of 73), while for the other parkinsonian syndromes it was 71.4% (50 out of 70).

46 supranuclear palsy is considered an atypical parkinsonian syndrome, it is not known whether patients

47 lysosomal ATPase ATP13A2, a gene linked to a parkinsonian syndrome (Kufor-Rakeb syndrome), in brain s

48 rty-seven patients with clinically uncertain Parkinsonian syndromes (mean age +/- SD, 56.9 +/- 14.9 y

49 anuclear palsy (the two most common atypical parkinsonian syndromes) on a single case basis.

50 ficient to distinguish between IPD and other parkinsonian syndromes, particularly in the early stages

51 high diagnostic accuracy for differentiating parkinsonian syndromes (PS), from essential tremor and p

52 Patients presenting with parkinsonian syndromes share many clinical features, whi

53 Patients with FoG, which is a feature of parkinsonian syndromes, show variability in gait metrics

54 In some patients with suspected parkinsonian syndromes, SPECT imaging with ((123)I)ioflu

55 that is difficult to distinguish from other parkinsonian syndromes such as multiple-system atrophy (

56 In comparison with other Parkinsonian syndromes the patients were older and had a

57 Fourteen patients with parkinsonian syndromes underwent (18)F-desmethoxyfallypr

58 When compared with other Parkinsonian syndromes, VP had an older age of onset.